Drug Profile
Research programme: cardiovascular disease gene/cell therapies - Anges/Tokyo Hospital
Latest Information Update: 03 Jan 2020
Price :
$50
*
At a glance
- Originator AnGes MG; University of Tokyo
- Class Cell therapies; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 03 Jan 2020 AnGes MG is now called AnGes
- 30 Aug 2005 This programme is still in active development
- 01 Feb 2005 Preclinical trials in Cardiovascular disorders in Japan (unspecified route)